Loading...
•
Mar 31, 2025
Bristol-Myers Squibb Q1 2025 Earnings Report
Bristol Myers Squibb reported lower revenues and higher profitability in Q1 2025 compared to the same quarter last year.
Key Takeaways
Bristol Myers Squibb posted a revenue decline but achieved strong profitability in Q1 2025, with a significant rebound in net income and EPS driven by the growth portfolio and cost control measures.
Total revenue was $11.2B, down 6% year-over-year.
GAAP net income reached $2.46B, reversing a prior year loss.
Growth portfolio revenue rose to $5.56B, led by Opdivo and Breyanzi.
Non-GAAP EPS improved to $1.80, up from a $4.40 loss last year.
Revenue by Geographic Location
Forward Guidance
BMS raised its 2025 revenue and non-GAAP EPS guidance, supported by strength in its growth portfolio and favorable FX impact.
Positive Outlook
- Raised 2025 revenue guidance to $45.8B–$46.8B
- Raised non-GAAP EPS guidance to $6.70–$7.00
- Strong performance from Growth Portfolio products
- Improved royalty and interest income outlook
- Benefit from favorable foreign exchange trends
Challenges Ahead
- Ongoing generic erosion in Legacy Portfolio
- Revlimid, Sprycel, and Abraxane revenues declined sharply
- Gross margin declined to 72.9% GAAP
- Continued Medicare Part D impact on U.S. sales
- Mixed results from recent clinical trials in pipeline
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...